Frexalimab, a therapy Sanofi is developing for multiple sclerosis (MS) patients, led to sustained reductions in disease activity in people with relapsing forms of MS over more than two years […]
The post ECTRIMS 2025: Frexalimab shows long-term benefits for MS patients appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com